Screener
Ionis Pharmaceuticals IONS Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpense.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Income (loss) from operations | (102,293) | 139,816 | (219,714) | (7,045) |
| Other income (expense): | ||||
| Investment income | 20,230 | 24,687 | 45,713 | 49,354 |
| Interest expense | (4,618) | (4,114) | (9,778) | (8,223) |
| Interest expense related to sale of future royalties | (17,506) | (18,648) | (34,843) | (37,470) |
| Gain (loss) on investments, net | (10,182) | (18,312) | 12,401 | (20,476) |
| Other income, net | 987 | 102 | 529 | 569 |
| Income (loss) before income tax benefit (expense) | (113,382) | 123,531 | (205,692) | (23,291) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's interest expense?
- Ionis Pharmaceuticals (IONS) reported interest expense of $4.62M in Q2 2026.
- How has Ionis Pharmaceuticals's interest expense changed year-over-year?
- Ionis Pharmaceuticals's interest expense increased by 12.3% year-over-year, from $4.11M to $4.62M.
- What is the long-term trend for Ionis Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's interest expense has grown at a 16.6% compound annual growth rate (CAGR), from $9.35M to $17.26M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Ionis Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude